BackCortexyme Overview

Cortexyme Total Assets

Cortexyme's total assets is $120M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$124.00M
↑ 5.79% YoYΔ $6.79M vs prior year quarter

Peer trimmed avg / median

Loading

Cortexyme Total Assets History

Loading

Cortexyme vs. peers: Total Assets Comparison

Loading

Cortexyme Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cortexyme (CRTX) FAQ

As of the most recent data (June 2026), CRTX shows a total assets of $120M. That compares with $120M in the prior-year period — up 5.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CRTX's total assets is now $120M (was $120M) — a 5.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Cortexyme is outperforming or lagging.

Tracking CRTX's total assets over time shows whether Cortexyme is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $120M in the prior-year period — up 5.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Cortexyme's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $120M) with ownership activity and broader fundamentals.

Cortexyme's total assets is $120M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.